BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Lupin receives Tentative Approval for Generic Cymbalta® Delayed-release Capsules

Mumbai / Baltimore, December 09, 2011: Pharma Major Lupin Limited, announced today that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Duloxetine Hydrochloride Delayed-release (HCl DR) Capsules 20 mg, 30 mg and 60 mg from the United States Food and Drugs Administration for the company's Abbreviated New Drug Application (ANDA) to market a generic version of Eli Lily & Company's Cymbalta® Delayed-release Capsules.

Lupin's Duloxetine HCl DR Capsules are the AB-rated generic equivalent of Eli Lily's Cymbalta® Delayed-release Capsules 20 mg, 30 mg and 60 mg strengths. Duloxetine HCl DR Capsules is indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy, management of fibromyalgia (FM) and management of chronic musculoskeletal pain.

Cymbalta® HCl DR Capsules 20 mg, 30 mg, 60 mg had annual U.S sales of approximately US$ 3.5 billion for the twelve months ending Sep, 2011 (IMS Health data)

About Lupin Limited

Headquartered in Mumbai, India, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 Million (USD 1.28 Billion) and Rs. 8,626 Million (USD 193 Million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd.

About Lupin Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is committed to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com

For further information please contact:

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:

Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com or

Sonia Mansata
Text 100 Public Relations
Ph: +91 98 20 11 2481
Email: sonia.mansata@text100.co.in

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release

* *Cymbalta Delayed-release Capsules are a registered copyright / trademark of Eli Lilly & Company.*